In earlier studies of the influence of hydroxymethylglutaryl-coenzyme A reductase inhibitors (also known as statins) on colorectal cancer prognosis, investigators reported a reduced rate of cancer-specific mortality. Studies of recurrence are few and small. Using data from Danish registries, we followed 21,152 patients diagnosed with stage I-III colorectal cancer from 2001 to 2011. We estimated the association between statin use in the preceding year and cancer recurrence, cancer-specific mortality, and all-cause mortality rates. We identified 5,036 recurrences, 7,084 deaths from any cause, and 4,066 deaths from colorectal cancer. After adjustment for potential confounders, statin use was not associated with recurrence (adjusted hazard ratio (aHR) = 1.01, 95% confidence interval (CI): 0.93, 1.09), but it was associated with death from colorectal cancer (aHR = 0.72, 95% CI: 0.65, 0.79) and death from any cause (aHR = 0.72, 95% CI: 0.67, 0.76). Statin use in the year preceding recurrence was associated with a reduced risk of cancer-specific mortality (aHR = 0.83, 95% CI: 0.74, 0.92) but also a reduced risk of death from any other cause (aHR = 0.78, 95% CI: 0.61, 1.00). Statin use was not associated with a reduced rate of colorectal cancer recurrence, but it was associated with a reduced rate of cancer-specific mortality, which suggests that there is no cancer-directed benefit; therefore, there is no basis to prescribe statins to colorectal cancer patients who do not have cardiovascular indications. colorectal neoplasms, epidemiology; colorectal neoplasms, secondary; HMG CoA reductase inhibitors Abbreviations: aHR, adjusted hazard ratio; CI, confidence interval; DCCG, Danish Colorectal Cancer Group; HR, hazard ratio.
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In addition to preventing myocardial infarction (1-3), hydroxymethylglutaryl-coenzyme A reductase inhibitors (also known as statins) have antiinflammatory and antioxidative effects (4) . These and other pleiotropic effects may influence cancer incidence and prognosis (5, 6) . Although the evidence regarding the influence of statins on colorectal cancer incidence has been mixed (7, 8) , studies of statin use and colorectal cancer prognosis have more consistently shown a beneficial association (9) (10) (11) (12) . Mechanisms by which statins might improve colorectal cancer prognosis include sensitization to and induction of apoptosis (13, 14) , reduction of the potential for cell migration (13, 15) , and suppression of survivin expression (13) . Statins may also augment the effectiveness of chemotherapy and neoadjuvant chemoradiotherapy (13, 16, 17) .
Meta-analyses of the association between statin use and colorectal cancer prognosis have been focused on mortality rates (9, 10) and are heavily weighted toward the results of 2 studies (11, 12) . The summary association between prediagnostic statins use and colorectal cancer-specific mortality had a hazard ratio of 0.80 (95% confidence interval (CI): 0.77, 0.84); the association with postdiagnostic statins use had a hazard ratio of 0.70 (95% CI: 0.60, 0.82) (10) . However, in the same meta-analysis, the authors reported a near null association with recurrence-free survival (hazard ratio (HR) = 0.98, 95% CI: 0.36, 2.70) (10) based on 2 small studies with point estimates on opposite sides of the null (18, 19) .
If statin use reduces the risk of death from colorectal cancer, the effect would likely be mediated by a reduced hazard of colorectal cancer recurrence. To reconcile the protective summary association between statin use and colorectal cancerspecific mortality rates with the null summary association with recurrence, we undertook a large cohort study of the associations of statin use with both colorectal cancer recurrence and mortality rates nested in Danish health registries.
METHODS
The study protocol was approved by the Danish Data Protection Agency (2011-41-6968) and the North Denmark Region Committee on Health Research Ethics (N-20130027). Informed consent is not required for registry-based research.
Data sources
Records from Danish medical registries were linked using the Central Personal Registry number, an identification number assigned to Danish citizens and legal residents. The cohort was identified from the Danish Colorectal Cancer Group (DCCG) database, a nearly complete clinical registry of colorectal cancer patients (20) (21) (22) . This database provided information on dates of surgery and diagnosis, stage at diagnosis, surgical urgency, and receipt of chemotherapy. The Danish Central Personal Registry tracks death and emigration (23) . These variables were used for the overall mortality outcome and to censor follow-up. To exclude patients with a history of cancer, we linked to the Danish Cancer Registry (24) . The Danish National Patient Registry (25) records information on patients discharged from nonpsychiatric hospitals, emergency rooms, and outpatient clinics. Each discharge or outpatient visit is recorded with 1 primary diagnosis and secondary diagnoses classified according to the International Classification of Diseases, 10th Revision. Procedure codes are also recorded for inpatient and outpatient admissions. The Danish Pathology Registry receives data from the Danish Pathology Data Bank (26) . Danish pathology departments record data on biological specimens according to national guidelines using the Danish version of the Systemized Nomenclature of Medicine codes. The Danish National Registry of Medicinal Products maintained by Statistics Denmark records prescriptions redeemed at Danish pharmacies, including the date dispensed, drug prescribed (according to the Anatomical Therapeutic Chemical classification), and fill quantity (27) . The Danish Register of Causes of Death records deaths in Denmark and includes the underlying cause of death and a sequence of 1-4 contributory causes coded using the International Classification of Diseases, 10th Revision (28).
Study population
The DCCG recorded the date of colorectal cancer diagnosis as the date of the first hospital contact resulting in a diagnosis of colorectal cancer. We included colorectal cancer patients who had surgery within 60 days of diagnosis and were registered with the DCCG between May 1, 2001 , and December 31, 2011. We excluded patients with metastases or T0 cancer stage and patients with a diagnosis of colorectal cancer or metastases in Danish National Patient Registry or Danish Cancer Registry more than 180 days before the DCCG date of diagnosis. We also excluded patients with a diagnosis of cancer other than colorectal cancer, metastases, or nonmelanoma skin cancer at any time before the colorectal cancer diagnosis.
Colorectal cancer outcomes
We defined colorectal cancer recurrence as tumor growth at or near the site of the original tumor and in the same organ or metastases to tissue adjacent to the original tumor site or to a distant organ. We have previously described and validated an algorithm to identify these recurrences among Danish colorectal cancer patients (29) . This algorithm relies on: 1) International Classification of Diseases, 10th Revision, codes for metastatic cancer and procedure codes for chemotherapy from the Danish National Patient Registry (25) (the Danish National Patient Registry has 94% sensitivity and 100% specificity for classification of receipt of chemotherapy in colorectal cancer patients) (30), 2) metastases registered in the Danish National Patient Registry or Danish Cancer Registry, and 3) histologically diagnosed recurrences in the Danish Pathology Registry. Compared with active follow-up of colorectal cancer patients for recurrence, our algorithm had sensitivity of 95%, specificity of 97%, positive predictive value of 86%, and negative predictive value of 99%.
We identified deaths and dates of death from any cause using the Danish Central Personal Registry and deaths and dates of death with colorectal cancer as the underlying cause using the Danish Register of Causes of Death. In a sensitivity analysis, we included death from colorectal cancer as a recurrence in cases in which no recurrence was noted preceding that death.
Medications
We classified statin exposure as a time-varying dichotomous variable updated yearly after colorectal cancer surgery. In each yearly interval, patients were classified as exposed to statins if they had at least 1 prescription recorded in the Danish National Registry of Medicinal Products with an Anatomical Therapeutic Chemical code beginning with "C10AA"; otherwise, they were classified as unexposed. This exposure status was applied to the following year of follow-up. Use of aspirin (Anatomical Therapeutic Chemical codes B01AC06, N02BA01, and N02BA51) or other nonsteroidal antiinflammatory drugs (Anatomical Therapeutic Chemical code M01A) was similarly classified. Aspirin and other nonsteroidal antiinflammatory drugs are available over the counter in small amounts for analgesia, but regular users ordinarily receive a prescription, the cost of which is reimbursed by the Danish health-care system. 
Statistical analysis
We calculated the frequencies and proportions of cohort members within categories of covariates and medication use. We used proportional hazards regression to estimate the hazard ratio for the associations of time-varying use of statins with rates of colorectal cancer recurrence, colorectal cancer-specific mortality, and death from any cause, with adjustment for covariates. Follow-up began 180 days after colorectal cancer diagnosis and ended at the occurrence of the event of interest, with censoring at date of death, at lossto-follow-up, or on December 31, 2012, whichever came first. As a sensitivity analysis, we repeated the analysis with the population limited to patients who underwent elective surgery. Given the initial results, we more closely evaluated a potential cancer-directed effect of statins by using proportional hazards regression to estimate the hazard ratio for the associations of statin use in the year before a colorectal cancer recurrence with rates of colorectal cancer-specific mortality or death from any cause except colorectal cancer with adjustment for covariates. Follow-up began at the date of recurrence and ended at the occurrence of the event of interest, with censoring at loss-to-follow-up or December 31, 2012, whichever came first. We also compared the sites of recurrence in both those who used statins and those who did not in the year before diagnosis. We repeated the main analyses within strata of demographic, tumor, and treatment characteristics while recognizing that we had no prior hypothesis pertaining to modification of statin's effect on colorectal cancer outcomes by other covariates. A.R. used SAS software, version 9.2 (SAS Institute, Inc., Cary, North Carolina), to analyze the data.
RESULTS
The DCCG identified 34,801 colorectal cancer patients. Of these, we excluded 4,649 who had metastatic disease at diagnosis, 4,189 who had an unknown cancer stage at diagnosis, and 94 who had no evidence of a primary tumor (T0). Of the remaining 25,963 patients with stage I, II, or III colorectal cancer, we excluded 2,312 because they previously had a cancer other than nonmelanoma skin cancer, 143 because they had metastases more than 180 days before the colorectal cancer diagnosis, 20 because they had an earlier colorectal cancer diagnosis more than 180 days before the present date of colorectal cancer diagnosis, 73 who were not found in the Central Personal Registry, and 10 who had a colorectal cancer diagnosis date more than 60 days after date of surgery. We also excluded patients with events within 180 days of their colorectal cancer diagnosis that would complicate identification of a recurrence, including 779 with a new primary cancer, 1 with a potential colorectal cancer recurrence that may have been residual primary disease, and 2,220 who died. Some patients were excluded for more than 1 reason. Eighty percent of patients had surgery with 39 days of diagnosis (median, 18 days), and statin use in the year preceding diagnosis was not associated with mortality rates in the 90 days after surgery (adjusted hazard ratio (aHR) = 0.80, 95% CI: 0.29, 2.23). After exclusions, there were 21,152 eligible cohort members. Table 1 presents descriptive characteristics of the study participants. We identified 5,036 recurrences, 7,084 deaths from any cause, and 4,066 deaths from colorectal cancer.
Having an advanced-stage cancer and receiving treatments that are more often offered to patients with advanced-stage cancer were positively associated with rates of recurrence, all-cause mortality, and colorectal cancer-specific mortality ( Table 2) . Increasing age and Charlson comorbidity score were little associated with rates of recurrence but strongly associated with rates of both all-cause and colorectal cancerspecific mortality. History of inflammatory bowel disease was most strongly associated with recurrence rates.
Approximately 31% of the cohort participants were ever prescribed a statin, 35% were prescribed aspirin, and 49% were prescribed another nonsteroidal antiinflammatory drug. Use of statins in the preceding year was not associated with the risk of colorectal cancer recurrence (aHR = 1.01, 95% CI: 0.93, 1.09) but was associated with a reduced risk of death from colorectal cancer (aHR = 0.72, 95% CI: 0.65, 0.79) and death from any cause (aHR = 0.72, 95% CI: 0.67, 0.76). Results changed little when the population was limited to colorectal cancer patients who underwent elective surgery (for recurrence, aHR = 1.01, 95% CI: 0.93, 1.10; for death from colorectal cancer, aHR = 0.71, 95% CI: 0.64, 0.78; and for death from any cause, aHR = 0.71, 95% CI: 0.67, 0.76). In a sensitivity analysis, we counted the 1,217 persons who died of colorectal cancer but did not have a preceding record of recurrence as having had a recurrence on the date of their death. The adjusted hazard ratio for the association between use of statins in the preceding year and the risk of this redefined colorectal cancer recurrence was 0.92 (95% CI: 0.86, 0.99).
The precisely estimated near null association between statin use and recurrence rate, combined with the precisely estimated protective association between statin use and colorectal cancer-specific mortality rate, led us to conduct a secondary analysis of whether statin use before a recurrence is associated with a reduced risk of colorectal cancer-specific mortality or a different distribution of recurrence sites. The goal was to see whether statins beneficial association with the rate of colorectal cancer mortality accrued only after a recurrence occurred. Of the 5,036 patients with a recurrence of colorectal cancer, 20% had used statins in the preceding year. Use of statins in the year preceding the colorectal cancer recurrence was associated with a reduced risk of colorectal cancer-specific mortality (494 deaths among users and 2,357 deaths among non-users; aHR = 0.83, 95% CI: 0.74, 0.92) and with a reduced risk of death from any cause except colorectal cancer (104 deaths among users and 389 deaths among non-users; aHR = 0.78, 95% CI: 0.61, 1.00). The distributions of sites of recurrence were comparable between statin users and non-users in the year before recurrence ( Table 3 ). The associations between use of statins in the preceding year and colorectal cancer outcomes were mainly homogeneous within strata of demographic, tumor, and 
DISCUSSION
In what is to our knowledge the largest study to date of this association, we found a near null association between time-varying use of statins-with prescriptions lagged by 1 year-and the risk of colorectal cancer recurrence. We found a protective association between use of statins and the hazards of colorectal cancer-specific mortality or death from any cause. Finally, the inconsistent association between recurrence and colorectal cancer-specific mortality rates led us to estimate the association of use of statins in the year before a recurrence with death from colorectal cancer and death from any cause except colorectal cancer. Both of these associations suggested that use of statins before cancer recurrence reduced the mortality risk.
The null association between statin use and colorectal cancer recurrence rate contrasts with results from a study of the association between prediagnostic use of statins and cancerspecific mortality rates among 43,487 Danish colon cancer patients diagnosed from 1995 to 2007 (11) , which overlapped our study population for 6 years. In that study, colon cancer patients who were prescribed a statin before diagnosis had a reduced risk of death with colon cancer as the underlying cause (HR = 0.81, 95% CI: 0.75, 0.87). This interval does not overlap the interval of our estimate of the association between statin use and recurrence rate (aHR = 1.01, 95% confidence interval: 0.93, 1.09), but it does overlap the interval of our estimate of the association between statin use and cancerspecific mortality rate (aHR = 0.72, 95% CI: 0.65, 0.79).
The results of Nielsen et al. (11) were similar to those from a study of 7,657 patients diagnosed with stage I-III colorectal cancer from 1998 to 2009 in the United Kingdom. In that study, Cardwell et al. (12) reported a hazard ratio of 0.72 (95% CI: 0.64, 0.81) for the association of postdiagnosis statin use-lagged by 6 months-with cancer-specific mortality. Between them, the Danish and United Kingdom studies contributed 83% of the weight to a recent meta-analysis that included 6 studies in all (10) and that reported protective summary estimates of association provided in the introduction. Most recently, Shao et al. (32) used data from the Taiwan cancer registry and administrative data to estimate the association between prediagnosis statin use and cancerspecific survival rates (HR = 0.77, 95% CI: 0.68, 0.88) in 17,115 patients with stage I-III colorectal cancer.
Earlier studies of the association between statin use and colorectal cancer recurrence are rare and small. Two studies of the association of statin use with recurrence or progression were nested in a trial of 842 patients with stage III colon cancer (HR = 1.14, 95% CI: 0.77, 1.69) (18) and in a registry of 407 patients with rectal cancer (HR = 0.44, 95% CI: 0.26, 0.75) (19) . In a study of 891 rectal cancer patients at 5 Canadian centers, investigators reported that statin use at initial consultation was favorably associated with pathologic complete response (odds ratio = 1.72, 95% CI: 1.02, 2.92) (33) . Finally, in a study of 2,697 German patients with colorectal cancer, Hoffmeister et al. (34) reported that the associations of statin use with recurrence-free survival (HR = 0.90, 95% CI: 0.63, 1.27) and mortality rate were near null.
Ours is the first study in which the association between statin use and colorectal cancer outcomes has been evaluated at all critical time points: before diagnosis, before recurrence, and after recurrence. We found the same protective associations of statin use with colorectal cancer-specific mortality rate and all-cause mortality rate that were reported in earlier, large studies. Our null association between statin use and colorectal cancer recurrence argues against a cancer-directed effect of statin use and calls into question the mechanism by which the protection against mortality rate arises. We did observe a protective association between statin use in the year before recurrence and colorectal cancer-specific mortality rate, but statin use in the year before recurrence was also protective against death from other causes. The distributions of sites of recurrence were similar between statin users and nonusers, further arguing against a cancer-directed effect. In a recent randomized trial of patients with stage IV colorectal cancer who had adequate function of major organs, researchers found that adding 40 mg per day of simvastatin to guideline chemotherapy did not benefit progression-free survival or overall survival (35) .
Healthy-user bias and lead-time bias provide 2 reasonable explanations for the observed protective associations of statins in the year before recurrence with death from colorectal cancer and death from another cause. Although Danish statin users do not generally have better health or health behaviors than do non-users (36), colorectal cancer patients who continue to take statins after their diagnosis may have healthier lifestyles or a better cancer prognosis. It is also possible that the colorectal cancer patients who continue to take statins after their diagnoses more often contact the health-care system, so their recurrences may be diagnosed earlier than those in non-users. This would result in more elapsed time between recurrence and death among statin users and downwardly bias mortality rates. Weighing against this explanation is that all Danes have unfettered access to health care and that all Danish colorectal cancer patients are invited to undergo standardized follow-up visits. These visits include computed tomography scans 1 and 3 years after diagnosis and colonoscopy every 5 years after diagnosis until age 75 years. This guideline surveillance program has been in place since 2006, before which similar but not standardized programs were used at different hospitals.
A limitation of the present study and the other earlier studies is the inability to implement an active comparator design (37) . This design would compare colorectal cancer outcomes in users of statins with outcomes in users of another cholesterollowering agent, such as a bile acid sequesterant or ezetimibe. These agents are most often prescribed in combination with statins when statins alone fail to adequately control cholesterol or are prescribed alone when statins are poorly tolerated. They are seldom prescribed alone as first-line therapy to manage cholesterol levels. Thus, an active comparator design with users of these medications as the reference group would not compare persons with equivalent indications.
In conclusion, our results reproduce those from earlier large and influential studies in which a protective association between statins use and colorectal cancer mortality rate was found. This association, however, appears to arise not from a protective effect of statins against colorectal cancer recurrence rate but possibly from a protective association with postrecurrence mortality rate. The same protective association pertains to deaths from colorectal cancer and from causes other than colorectal cancer, which again casts doubt on a direct cancer benefit from statins use. In combination, these results provide no basis to prescribe statins to patients with newly diagnosed colorectal cancer who do not have cardiovascular indications.
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